Nowadays there are clinical reports of the effectiveness of combining selective COX-2 inhibitors with chemotherapy to treat digestive tract tumors, but the exact mechanism underlying the anti-tumor effects remain unclear (Dawson et al., 2007; Altorki et al., 2011). Here, PTGS2 is linked to neoplasm.